SAN FRANCISCO -- Radiation therapy (RT) after surgery for high-risk muscle-invasive bladder cancer significantly reduced the rate of local recurrence and improved survival, according to a randomized ...

A large electronic health record study suggests that difficulty recognizing painless blood in urine may delay diagnosis and worsen long-term survival for bladder cancer patients with color vision ...

A study using a large electronic health record database found that patients with colour vision deficiency had lower survival rates for bladder cancer, possibly because they may not be able to detect ...

Bladder cancer (BCa), a common type of urothelial carcinoma in the urinary system, ranks as the tenth most prevalent malignancy worldwide and remains one of the leading causes of cancer-related ...

Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Immunocompromised patients with bladder had a higher risk of disease progression and recurrence when compared to their non-immunocompromised counterparts. Immunocompromised patients with bladder ...

Also Read: ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug Specific key efficacy findings from cohort B (N=80) of the Phase 2/3 open-label, single-arm ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...

SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented ...

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill ...